The CSL Limited (ASX:CSL) share price is down 24% from its peak – is it time to buy?

The CSL Limited (ASX: CSL) share price is down 24% from its 52 week high. Are the shares cheap now?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is down 24% from its 52-week high of $232 per share and whilst the broader market has also suffered in recent weeks, it's worth considering whether now is a good time to buy CSL shares.

The quality of CSL as a business is well known. It is one of the ASX's premier biotechnology companies along with Mayne Pharma Group Ltd (ASX: MYX) and Clinuvel Pharmaceuticals Limited (ASX: CUV). It has also managed to grow revenues and profits consistently while continuing to serve a large market.

The challenge for investors who don't already own CSL shares is that the market recognises that quality and reflects it in the share price. As such, the valuation of the company's shares has always been quite high.

So, with the shares down 24% from their peak, is now a good time to buy CSL shares? Let's look at a few metrics.

FY 2018 FY 2017
Revenue US$7,915 million US$6,947 million
Net Profit US$1,729 million US$1,337 million
Profit Margin 22% 19%
Market Cap A$80 billion (approx US$57 billion) Approx A$74 billion (US$52 billion) as at 30 June 2017
Price to Sales ratio 7.2 times 7.5 times
Price to Earnings ratio 33 times 39 times
Sales Growth rate (1 yr forecast) 9%
Underlying Profit Growth rate (1 yr forecast) 10% – 14%

*Source: CSL annual report and investor presentation

Interestingly, CSL's profit margins are expanding which is why the company is expecting profit growth to be higher than sales growth.

CSL's FY 18 dividend was US$1.51 per share, its current share price is A$177 (approx US$126) and I estimate a 12% expected annual return on CSL shares (equities as an asset class tend to average about 10% over time and I would expect CSL to perform better than average).

Given that information, I estimate that CSL is trading at an implied growth rate of 10% – 12%.

As such, I think CSL shares are fairly priced at the moment. I don't think they are ridiculously cheap, and I also don't think they are too expensive.

What now?

Since there is no margin for error in my back of the envelope calculations, I'm not jumping in to buy CSL shares right now. If the shares dip a little further, then I will definitely be tempted to open a position although I'm fully aware that this might not happen.

Instead, I might focus on these three revolutionary companies.

Motley Fool contributor Kevin Gandiya has no position in any of the stocks mentioned. You can find Kevin on Twitter @KevinGandiya. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »